# Phase 1 Study of KH607 Tablets

> **NCT06393803** · PHASE1 · RECRUITING · sponsor: **Chengdu Kanghong Pharmaceutical Group Co., Ltd.** · enrollment: 88 (estimated)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** 2mg KH607 tablets
- **DRUG:** 5mg KH607 tablets
- **DRUG:** 10mg KH607 tablets
- **DRUG:** 20mg KH607 tablets
- **DRUG:** 30mg KH607 tablets
- **DRUG:** 40mg KH607 tablets
- **DRUG:** 50mg KH607 tablets
- **DRUG:** 60mg KH607 tablets

## Key facts

- **NCT ID:** NCT06393803
- **Lead sponsor:** Chengdu Kanghong Pharmaceutical Group Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-10-21
- **Primary completion:** 2024-10-30
- **Final completion:** 2024-10-30
- **Target enrollment:** 88 (ESTIMATED)
- **Last updated:** 2024-05-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06393803

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06393803, "Phase 1 Study of KH607 Tablets". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06393803. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*